A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Feb 2020 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Results (n=117) from NCT0277039, NCT01875250 and NCT01867333 assessing whether enzalutamide and apalutamide suppress 11beta-hydroxysteroid dehydrogenase-2 eading to elevated cortisol concentrations, increased ratio of active to inactive glucocorticoids and possibly suboptimal response to immunotherapy, published in the Annals of Oncology
- 17 Oct 2019 Planned End Date changed from 1 Feb 2021 to 30 Jun 2020.